Evaluation of Long-Acting Lenacapavir for the Treatment of HIV-1 in Treatment-experienced Adolescents and Children

Purpose

The goal of this clinical study is to learn more about the study drug, lenacapavir (LEN). The study will assess the safety, tolerability, and efficacy of long-acting LEN when combined with other medicines in adolescents and children living with HIV-1 who weigh at least 35 kg and have been treated before for HIV-1. The study will also see how easy it is for participants to take LEN as injection or an oral pill. The primary objectives are to evaluate the pharmacokinetics and safety of LEN in combination with optimized background regimen (OBR) in TE pediatric participants with HIV-1.

Condition

  • HIV-1-infection

Eligibility

Eligible Ages
Under 17 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Body weight at screening ≥ 35 kg. - On a stable failing antiretroviral (ARV) regimen for > 8 weeks before screening and willing to continue the regimen until Day 1. - Plasma HIV-1 RNA ≥ 400 copies/mL on at least 2 consecutive occasions spanning at least 6 months, including at screening. - Have previously changed their ARV regimen due to treatment failure. - ARV treatment options limited due to resistance, tolerability, contraindications, safety, drug access. - Able and willing to commit to taking LEN in combination with their OBR. - The following laboratory parameters at screening: 1. Estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73 m^2 using Bedside Schwartz Formula. 2. Absolute neutrophil count > 0.50 GI/L (> 500 cells/mm^3). 3. Hemoglobin ≥ 85 g/L (> 8.5 g/dL). 4. Platelets ≥ 50 GI/L (≥ 50,000/mm^3). 5. Hepatic transaminases (aspartate aminotransferase and alanine aminotransferase) ≤ 5 × upper limit of normal. 6. Total bilirubin ≤ 23 μmol/L (≤ 1.5 mg/dL) and direct bilirubin ≤ 7 μmol/L (≤ 0.4 mg/dL).

Exclusion Criteria

  • Life expectancy ≤ 1 year. - An opportunistic illness requiring treatment within the 30 days prior to screening. - Evidence of active pulmonary or extra-pulmonary tuberculosis within 3 months prior to screening. - Hepatitis C virus (HCV) antibody positive with detectable HCV RNA at screening. - Hepatitis B virus (HBV) surface antigen (HBsAg) positive or HBV core antibody (antibody against hepatitis B core antigen (anti-HBc)) positive; if individual is HBsAg negative and anti-HBc positive but HBV DNA undetectable, individual may be enrolled. Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Study Design

Phase
Phase 2
Study Type
Interventional
Allocation
N/A
Intervention Model
Single Group Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
LEN 		Participants will receive oral LEN 600 mg on Days 1 and 2. Participants will also receive 2 doses of LEN 927 mg as subcutaneous (SC) injection on Day 1 and Week 26 along with their OBR per clinical practice. At the Week 52, participants will be given the option to receive SC LEN every 6 months while continuing their OBR for at least another 2 SC LEN doses in the extension phase.
  • Drug: Oral Lenacapavir
    Tablets administered without regard to food
    Other names:
    • GS-6207
    • Sunlenca®
  • Drug: Subcutaneous Lenacapavir
    Administered via subcutaneous injections
    Other names:
    • GS-6207
    • Sunlenca®
  • Drug: Optimized Background Regimen (OBR)
    Optimized background regimen as prescribed by the Investigator

Recruiting Locations

Grady Health System, Ponce De Leon Center
Atlanta 4180439, Georgia 4197000 30308

More Details

Status
Recruiting
Sponsor
Gilead Sciences

Study Contact

Gilead Clinical Study Information Center
1-833-445-3230 (GILEAD-0)
GileadClinicalTrials@gilead.com